Feb 5 (Reuters) - GlaxoSmithKline Plc's quarterly
profit fell short of analysts' expectations on Wednesday, and
the drugmaker said it has begun its planned split into two
companies following the merger of its over-the-counter products
into a venture with Pfizer.
Sales rose 11% to 8.90 billion pounds ($11.62 billion) in
the three months ended Dec. 31 at constant currency, while
adjusted earnings were 24.8 pence per share.
Analysts on average had expected fourth-quarter earnings of
25.8 pence on turnover of 9 billion pounds, according to a
company-compiled consensus https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus
of 15 analysts.
($1 = 0.7662 pounds)
(Reporting by Pushkala Aripaka and Ankur Banerjee in Bengaluru;
Editing by Bernard Orr)